DATATRAK CRO Partners Expand Multi-Year Agreements

CLEVELAND, Feb. 3, 2015 /PRNewswire/ – DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced three CRO Enterprise Partners have expanded their agreements.  These industry-leading organizations have chosen to boost their global licensing capacity and extended their relationship with DATATRAK.

"These partners have challenged the norm in our industry and experienced the rewards of a unified platform," said Laurence P. Birch, Chairman and CEO, DATATRAK. "Complexities once considered unavoidable, including data integration, are a thing of the past when organizations choose DATATRAK. Benefits that were previously considered futuristic, like Cross-Study real time data reporting, are available right now from DATATRAK. We are transforming how clinical research is managed, improving patient safety by getting the right information to the right person to make informed decisions faster."

The latest enhancements to the DATATRAK ONE® Unified Experience™ challenge the industry to reevaluate their expectations of eClinical systems.  The Cross-Study Manager delivers real-time enterprise-wide reporting and analysis. The Scheduler removes the redundancy of establishing repeated actions, among other benefits.

The DATATRAK ONE® Unified Platform is the foundation of DATATRAK efficiencies, providing a single data source that powers all DATATRAK solutions, eliminating data integration and introducing online Cross-Study data reporting.  DATATRAK offers industry-leading system reliability powered by the cloud, with an exceptional User Interface and a greater overall value.

About DATATRAK International, Inc.
DATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Preclinical and Phase I - Phase IV drug and device studies in multiple languages throughout the world. DATATRAK is located in Cleveland, Ohio; Bryan, Texas; Cary (RTP), North Carolina, Chicago, Illinois; and London, England.  For more information, visit

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on November 13, 2014 announcing its results for the third quarter 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.